This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
News releases
Date
Language
Type of release
Company AnnouncementDownload
Full announcement
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development
Bagsværd, Denmark, 19 December 2012 - Novo Nordisk today announced the completion of the phase 3a programme for IDegLira, a fixed-ratio combination of insulin degludec (Tresiba®), a once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue, as well as the decision to initiate phase 3 development for FIAsp, a faster-acting formulation of insulin aspart (NovoRapid®).
Further information
| Media: | ||
| Mike Rulis | +45 4442 3573 | mike@novonordisk.com |
| Ambre Morley (US) | +1 609 216 5240 | abmo@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 83 / 2012
